GSA Capital Partners LLP Grows Stake in Allogene Therapeutics, Inc. $ALLO

GSA Capital Partners LLP grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 235.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 613,998 shares of the company’s stock after acquiring an additional 431,119 shares during the quarter. GSA Capital Partners LLP owned about 0.27% of Allogene Therapeutics worth $841,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. CANADA LIFE ASSURANCE Co boosted its position in shares of Allogene Therapeutics by 27.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 39,730 shares of the company’s stock valued at $50,000 after purchasing an additional 8,519 shares during the period. Zacks Investment Management grew its stake in Allogene Therapeutics by 2.7% during the 3rd quarter. Zacks Investment Management now owns 526,132 shares of the company’s stock worth $652,000 after buying an additional 13,831 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in Allogene Therapeutics by 19.6% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 85,720 shares of the company’s stock worth $106,000 after buying an additional 14,032 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Allogene Therapeutics by 1.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 894,314 shares of the company’s stock worth $1,109,000 after buying an additional 15,327 shares during the last quarter. Finally, Cerity Partners LLC grew its stake in Allogene Therapeutics by 5.2% during the 2nd quarter. Cerity Partners LLC now owns 400,267 shares of the company’s stock worth $452,000 after buying an additional 19,843 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Insiders Place Their Bets

In other Allogene Therapeutics news, CEO David D. Chang sold 47,763 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $2.47, for a total transaction of $117,974.61. Following the completion of the sale, the chief executive officer directly owned 5,150,599 shares of the company’s stock, valued at approximately $12,721,979.53. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 72,183 shares of company stock worth $177,771. 13.20% of the stock is currently owned by company insiders.

Allogene Therapeutics Trading Up 2.0%

Allogene Therapeutics stock opened at $2.00 on Friday. Allogene Therapeutics, Inc. has a twelve month low of $0.98 and a twelve month high of $4.46. The stock has a 50 day moving average of $2.32 and a two-hundred day moving average of $1.88. The stock has a market capitalization of $690.30 million, a price-to-earnings ratio of -2.60 and a beta of 0.46.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Equities analysts predict that Allogene Therapeutics, Inc. will post -0.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ALLO. HC Wainwright raised their price target on Allogene Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. JPMorgan Chase & Co. upgraded Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Thursday, April 16th. Citizens Jmp raised their price target on Allogene Therapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Tuesday, April 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Allogene Therapeutics in a research note on Friday, May 1st. Finally, Citigroup restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.52.

Allogene Therapeutics Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.